We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


5 February 2020 By Robert Cyran

The $217 bln U.S. drugmaker joins Pfizer and GSK with plans to separate its steady from fast-growing products. The former’s cash flow will appeal to investors seeking stability. The latter will have Keytruda, its monster cancer drug. But stodgier businesses can be the better bet.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)